Publication:
Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients

Loading...
Thumbnail Image
Date
2014-01-01
Authors
Cakirca, MUSTAFA
Soysal, Pinar
Zorlu, MEHMET
Kiskac, MUHARREM
Kanat, Mustafa
CIKRIKCIOGLU, Mehmet Ali
Karatoprak, CUMALİ
HURSITOGLU, Mehmet
Camli, AHMET ADİL
ERKOC, Reha
Journal Title
Journal ISSN
Volume Title
Publisher
Research Projects
Organizational Units
Journal Issue

Metrics

Search on Google Scholar

Abstract
Aims: A close association has been demonstrated between increased cardiovascular risk and high asymmetric dimethylarginine (ADMA) levels in type 2 diabetes mellitus (DM) patients. We planned to measure serum ADMA levels in type 2 DM patients using vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Materials and methods: A total of 68 type 2 DM patients who were on metformin were enrolled in the study. Based on the glycemic levels of patients, vildagliptin was added on to treatment in 33 patients. Patients were followed for 6 months. Serum ADMA, C-reactive protein, and fibrinogen levels were compared in groups of patients using metformin or metformin + vildagliptin, after 6 months. Results: Serum ADMA levels were found to be significantly lower in the group using vildagliptin compared to the group using metformin + vildagliptin (P<0.001). However, serum C-reactive protein and fibrinogen levels were statistically similar in the two study groups (P=0.34 and P=0.23, respectively). Conclusion: Metformin + vildagliptin treatment was observed to lower serum ADMA levels in type 2 DM patients. Our findings notwithstanding, large-scale prospective randomized controlled studies are warranted to conclude that vildagliptin provides cardiovascular protection along with diabetes regulation. Keywords: asymmetric dimethylarginine (ADMA); dipeptidyl peptidase-4 (DPP-4) inhibitor; type 2 diabetes mellitus; vildagliptin.
Description
Keywords
type 2 diabetes
Citation
Cakirca M., Karatoprak C., Zorlu M., Kiskac M., Kanat M., CIKRIKCIOGLU M. A. , Soysal P., HURSITOGLU M., Camli A. A. , ERKOC R., et al., -Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients-, DRUG DESIGN DEVELOPMENT AND THERAPY, cilt.8, ss.239-243, 2014
Page Views

0

File Downloads

1

Sustainable Development Goals